Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 5/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | EBP | Q15125 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21107507 | 0.93 | KDM4E (0.43) | KDM4EHTR1AADRA1BDRD2DRD3 | |
| SCHEMBL19969935 | 0.89 | HTR1A (0.39) | KDM4EHTR1AADRA1BDRD2DRD3 | |
| SCHEMBL22958640 | 0.86 | OPRM1 (0.40) | KDM4EDRD2DRD3CYP2D6S1PR1 | |
| SCHEMBL23135328 | 0.86 | DRD2 (0.49) | DRD2DRD3SIGMAR1CYP2D6CYP1A2 | |
| SCHEMBL24589644 | 0.86 | KDM4E (0.40) | KDM4EDRD2DRD3SIGMAR1CYP2D6 | |
| SCHEMBL24847793 | 0.82 | KDM4E (0.41) | KDM4EHTR1AADRA1BDRD2DRD3 | |
| SCHEMBL25622445 | 0.82 | OPRM1 (0.40) | KDM4EHTR1AADRA1BDRD2DRD3 | |
| SCHEMBL21107120 | 0.81 | TSHR (0.41) | KDM4EDRD2DRD3SIGMAR1S1PR1 | |
| SCHEMBL23900336 | 0.80 | CYP1A2 (0.46) | KDM4EDRD2DRD3SIGMAR1CYP2D6 | |
| SCHEMBL10263353 | 0.80 | TSHR (0.50) | KDM4EDRD3CYP2D6CYP1A2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081311-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20210087213-A1 | DIANILINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2021-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087213-A1 | DIANILINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY | ALK, BRAF, MUSK | KDM4E 1304/4885HTR1A 4194/4885ADRA1B 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.